Vemurafenib Recruiting Phase 1 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02818023Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma